HLS Therapeutics Q1 Earnings Call Highlights

Key Points

• Interested successful HLS Therapeutics Inc.? Here are 5 stocks we similar better.

• HLS reported Q1 gross of $12.9 million, up 2% twelvemonth implicit year, and reaffirmed its 2026 guidance for gross of $56 cardinal to $60 cardinal and adjusted EBITDA of $18.5 cardinal to $21 million.

• The institution said its recently launched cholesterin cause NILEMDO is showing aboriginal momentum, with astir CAD 250,000 shipped successful a small implicit a month, beardown doc response, and expanding backstage payer sum successful Canada.

• Vascepa growth helped offset softness successful Clozaril, portion HLS continued to delever its equilibrium sheet with nett indebtedness falling 17% from year-end 2025 and operating currency travel rising sharply twelvemonth implicit year.

HLS Therapeutics (TSE:HLS) reported humble first-quarter gross maturation and reaffirmed its 2026 outlook, portion absorption highlighted aboriginal momentum for the company’s recently launched cholesterin cause NILEMDO and continued deleveraging of its equilibrium sheet.

On a league telephone discussing results for the 3 months ended March 31, 2026, Chief Executive Officer Craig Millian said HLS is “in a precise favorable position,” citing maturation successful Vascepa, resilience successful Clozaril and what helium described arsenic a stronger operational and fiscal instauration pursuing ratio improvements and indebtedness reduction.

→ Micron Investors Face a High-Stakes Moment After the Latest Rally

Total gross for the 4th was $12.9 million, up 2% from $12.6 cardinal a twelvemonth earlier, according to Chief Financial Officer John Hanna. Vascepa nett income roseate 15% twelvemonth implicit twelvemonth to $4.8 million, portion combined Clozaril nett income successful Canada and the U.S. declined to $7.8 cardinal from $8.2 million.

Adjusted EBITDA was CAD 3.5 million, compared with CAD 3.8 cardinal successful the prior-year quarter. Management said the diminution reflected further commercialized spending tied to the NILEMDO launch, which is expected to beryllium concentrated successful the archetypal fractional of the year.

NILEMDO Launch Shows Early Momentum

→ How Bad Could Tesla’s Cybertruck Recall Be for Shares?

HLS commercially launched NILEMDO successful April, and Millian said the institution had shipped astir CAD 250,000 worthy of the merchandise aft conscionable implicit 1 afloat period connected the market. He said aggregate wholesalers had placed reorders and that play ex-factory income were increasing.

Chief Commercial Officer Brian Walsh said aboriginal doc effect has been strong, peculiarly among clinicians treating statin-intolerant patients. He cited a unsighted awareness, proceedings and usage survey completed successful January involving 70 people cardiologists and endocrinologists, which showed much than 90% full consciousness earlier promotion and much than 80% willingness to prescribe.